Table 1.

Subject disposition.

	Adjuvanted HAI-05			Unadjuvanted HAI-05	Placebo
	15 µg	45 µg	90 µg	90 µg
	n (%)	n (%)	n (%)	n (%)	n (%)
All subjects treated	18 (100)	20 (100)	20 (100)	20 (100)	22 (100)
Intent-to-treat population a	18 (100)	20 (100)	20 (100)	20 (100)	22 (100)
Per-protocol population b	18 (100)	20 (100)	20 (100)	20 (100)	22 (100)
Completed the study	16 (88.9)	20 (100)	19 (95.0)	20 (100)	21 (95.5)
Discontinued from the study c	2 (11.1)	0	1 (5.0)	0	1 (4.5)

^a: The “Intent-to-treat” population included all subjects who received one dose of vaccine.

^b: The “Per-protocol” population included all subjects who received two doses of vaccine and had a complete set of serum specimens for antibody determination.

^c: Reason for discontinuation: lost to follow-up.